Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 137Carcinoma, Non-Small-Cell Lung 38Carcinoma, Renal Cell 33Neoplasm Metastasis 32Prostatic Neoplasms 22Brain Neoplasms 21Lung Neoplasms 20Pancreatic Neoplasms 19Uveal Melanoma 17Neoplasms 17Carcinoma, Hepatocellular 13Breast Neoplasms 13Sarcoma 12Skin Neoplasms 10Kidney Neoplasms 10Urinary Bladder Neoplasms 9Squamous Cell Carcinoma of Head and Neck 9Glioblastoma 9Triple Negative Breast Neoplasms 8Ovarian Neoplasms 8Colorectal Neoplasms 8Carcinoma, Transitional Cell 8Small Cell Lung Carcinoma 7Multiple Myeloma 7Colonic Neoplasms 7Clear-cell metastatic renal cell carcinoma 7Recurrence 6Myelodysplastic Syndromes 6Diabetes Mellitus, Insulin-Dependent, 12 6Uterine Cervical Neoplasms 5

Interventions

HhAntag691 4tazarotene 2sonidegib 2Photochemotherapy 2Aminolevulinic Acid 21-phenyl-3,3-dimethyltriazene 2Watchful Waiting 1Solutions 1Sirolimus 1Red Light 1Nivolumab 1NVP-BKM120 1Microarray Analysis 1Mass Spectrometry 1Ipilimumab 1Gene Expression Profiling 1Comparative Genomic Hybridization 1Carnitine 1Blue Light 1Biopsy 1BMS-833923 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Basal Cell Nevus Syndrome × Ipilimumab × Clear all
NCT03767439 2019-12-18

Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome

Columbia University

Phase 2 Withdrawn
Dermatologic

Basal Cell Nevus Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡